Low dose radioactive iodine ablation therapy (1.11 GBq) for differentiated thyroid cancer in western Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-4972-0936
dc.authorid0000-0001-6410-0746
dc.contributor.authorErkek, B. Karasah
dc.contributor.authorGumusgoz, H. Sariyildiz
dc.contributor.authorOral, A.
dc.contributor.authorYazici, B.
dc.contributor.authorAkgun, A.
dc.date.accessioned2025-03-21T13:09:37Z
dc.date.available2025-03-21T13:09:37Z
dc.date.issued2024
dc.departmentEge Üniversitesi, Tıp Fakültesi, Dahili Bilimler Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractObjective: Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [131I]NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90-95% at 10 years) [131I]NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation. Methods: Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110 MBq (30mCi) [131I]NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed. Results: An excellent response was achieved in 77% of the entire group according to ATA criteria post- ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10 ng/ml and 5.35 ng/ml) were associated with unsuccessful ablation. Conclusions: Our results indicate that a 1110 MBq (30 mCi) ablation dose is sufficient to achieve an exce- llent response in most low-risk DTC cases 6-12 onths later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success. (c) 2024 Sociedad Espanola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espana, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
dc.identifier.citationErkek, B. K., Gumusgoz, H. S., Oral, A., Yazici, B., & Akgun, A. (2024). Low dose radioactive iodine ablation therapy (1.11 GBq) for differentiated thyroid cancer in western turkey. Revista Española De Medicina Nuclear e Imagen Molecular, 43(6.
dc.identifier.doi10.1016/j.remn.2024.500055
dc.identifier.endpage5
dc.identifier.issn2253654X
dc.identifier.issue6
dc.identifier.scopus2-s2.0-85207320016
dc.identifier.scopusqualityQ4
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1016/j.remn.2024.500055
dc.identifier.urihttps://hdl.handle.net/11454/116879
dc.identifier.volume43
dc.identifier.wosWOS:001354720700001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorErkek, B. Karasah
dc.institutionauthorGumusgoz, H. Sariyildiz
dc.institutionauthorOral, A.
dc.institutionauthorYazici, B.
dc.institutionauthorAkgun, A.
dc.institutionauthorid0000-0002-4972-0936
dc.institutionauthorid0000-0001-6410-0746
dc.language.isoen
dc.publisherElsevier Espana S.L.U
dc.relation.ispartofRevista Española de Medicina Nuclear e Imagen Molecular
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subject131-I therapy
dc.subjectRemnant ablation
dc.subjectThyroglobulin
dc.subjectThyroid cancer
dc.titleLow dose radioactive iodine ablation therapy (1.11 GBq) for differentiated thyroid cancer in western Turkey
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu